A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies

Trial Profile

A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LUME-Colon 1
  • Sponsors Boehringer Ingelheim; Unilfarma
  • Most Recent Events

    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.
    • 21 Jan 2017 Results of prespecified subanalysis presented at the 2017 Gastrointestinal Cancers Symposium
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top